An acellular pertussis vaccine in healthy adults: Safety and immunogenicity

Edward P. Rothstein, Edwin L. Anderson, Michael D. Decker, Gregory A. Poland, Keith S. Reisinger, Mark M. Blatter, Robert M. Jacobson, Chrisanna M. Mink, Daniel Gennevois, Allen E. Izu, F. Sinangil, Andria G.M. Langenberg

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject- blinded study, adults (≥18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.

Original languageEnglish (US)
Pages (from-to)2999-3006
Number of pages8
Issue number23-24
StatePublished - Aug 6 1999


  • Acellular pertussis vaccine
  • Adult immunization

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'An acellular pertussis vaccine in healthy adults: Safety and immunogenicity'. Together they form a unique fingerprint.

Cite this